Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival...
Đã lưu trong:
| Tác giả chính: | |
|---|---|
| Tác giả khác: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Được phát hành: |
2025
|
| Những chủ đề: | |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| Tóm tắt: | <p>Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 inhibition in combination with chemotherapy among patients with advanced NSCLC, according to ATM/TP53 co-mutation status.</p> |
|---|